Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May 8:1:30.
doi: 10.3410/M1-30.

The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities

John Yost  1 , Johann E Gudjonsson
Affiliations

The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities

John Yost et al. F1000 Med Rep. .

Abstract

Over the past several years, tumor necrosis factor (TNF) antagonists have become first-line agents in the treatment of moderate-to-severe psoriasis. These medications are highly effective in treating both psoriasis and psoriatic arthritis and may also reduce the risk of cardiovascular events in patients with chronic inflammatory disorders. In this article we review the use of anti-TNF therapy in psoriasis and its implications in regards to the co-morbid conditions associated with psoriasis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. The biological effects of TNFα [27]
Figure 2.
Figure 2.. Dosing regimens for the three TNF antagonists
See this image and copyright information in PMC

References

    1. Gudjonsson JE, Elder J. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine. 7. New York: McGraw-Hill; 2008. p. 169.
    1. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, Novitskaya I, Khatcherian A, Bluth MJ, Lowes MA, Krueger JG. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204:3183–94. doi: 10.1084/jem.20071094. - DOI - PMC - PubMed

    2. <ext-link ext-link-type="uri" xlink:href="http://F1000medicine.com/article/id/1115570">F1000 Factor 3.0 Recommended</ext-link>

      Evaluated by David Fiorentino 16 Jul 2008

    1. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;75:2721–9. - PubMed
    1. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev. 2007;6:515–9. doi: 10.1016/j.autrev.2006.12.002. - DOI - PubMed
    1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50. doi: 10.1016/j.jaad.2008.02.039. - DOI - PubMed